- Home
- JYNT vs ABOS Comparison
JYNT vs ABOS Comparison
Compare JYNT & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYNT
- ABOS
- Stock Information
- Founded
- JYNT 2010
- ABOS 1996
- Country
- JYNT United States
- ABOS United States
- Employees
- JYNT N/A
- ABOS N/A
- Industry
- JYNT Multi-Sector Companies
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- JYNT Miscellaneous
- ABOS Health Care
- Exchange
- JYNT Nasdaq
- ABOS Nasdaq
- Market Cap
- JYNT 170.3M
- ABOS 84.2M
- IPO Year
- JYNT 2014
- ABOS 2021
- Fundamental
- Price
- JYNT $10.06
- ABOS $1.32
- Analyst Decision
- JYNT Strong Buy
- ABOS Strong Buy
- Analyst Count
- JYNT 3
- ABOS 3
- Target Price
- JYNT $16.33
- ABOS $8.00
- AVG Volume (30 Days)
- JYNT 90.7K
- ABOS 185.8K
- Earning Date
- JYNT 11-06-2025
- ABOS 11-11-2025
- Dividend Yield
- JYNT N/A
- ABOS N/A
- EPS Growth
- JYNT N/A
- ABOS N/A
- EPS
- JYNT N/A
- ABOS N/A
- Revenue
- JYNT $53,449,713.00
- ABOS N/A
- Revenue This Year
- JYNT $8.06
- ABOS N/A
- Revenue Next Year
- JYNT $11.18
- ABOS N/A
- P/E Ratio
- JYNT N/A
- ABOS N/A
- Revenue Growth
- JYNT 277.36
- ABOS N/A
- 52 Week Low
- JYNT $9.58
- ABOS $0.86
- 52 Week High
- JYNT $13.47
- ABOS $3.36
- Technical
- Relative Strength Index (RSI)
- JYNT 31.98
- ABOS 44.95
- Support Level
- JYNT $10.47
- ABOS $1.34
- Resistance Level
- JYNT $10.74
- ABOS $1.47
- Average True Range (ATR)
- JYNT 0.26
- ABOS 0.08
- MACD
- JYNT -0.04
- ABOS -0.01
- Stochastic Oscillator
- JYNT 5.26
- ABOS 8.16
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.